JP2024521792A5 - - Google Patents
Info
- Publication number
- JP2024521792A5 JP2024521792A5 JP2023572828A JP2023572828A JP2024521792A5 JP 2024521792 A5 JP2024521792 A5 JP 2024521792A5 JP 2023572828 A JP2023572828 A JP 2023572828A JP 2023572828 A JP2023572828 A JP 2023572828A JP 2024521792 A5 JP2024521792 A5 JP 2024521792A5
- Authority
- JP
- Japan
- Prior art keywords
- composition according
- sirna
- nucleotide
- composition
- antisense
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163193573P | 2021-05-26 | 2021-05-26 | |
| US63/193,573 | 2021-05-26 | ||
| PCT/US2022/031115 WO2022251484A1 (en) | 2021-05-26 | 2022-05-26 | Treatment of complement-mediated disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024521792A JP2024521792A (ja) | 2024-06-04 |
| JP2024521792A5 true JP2024521792A5 (cg-RX-API-DMAC7.html) | 2025-06-02 |
Family
ID=84229204
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023572828A Pending JP2024521792A (ja) | 2021-05-26 | 2022-05-26 | 補体媒介性疾患の治療法 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20250002910A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4346844A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024521792A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022251484A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11510939B1 (en) | 2019-04-19 | 2022-11-29 | Apellis Pharmaceuticals, Inc. | RNAs for complement inhibition |
| IL307721A (en) * | 2021-04-20 | 2023-12-01 | Astrazeneca Ireland Ltd | Compounds and methods for inhibiting expression of component 3 |
| WO2024081954A2 (en) * | 2022-10-14 | 2024-04-18 | Sanegene Bio Usa Inc. | Small interfering rna targeting c3 and uses thereof |
| EP4600358A4 (en) * | 2023-04-14 | 2026-05-20 | Rigerna Therapeutics Suzhou Co Ltd | COMPOUND TO INHIBIT C3 GENE EXPRESSION, PHARMACEUTICAL COMPOSITION AND ASSOCIATED USES |
| IL320833A (en) * | 2023-04-14 | 2025-07-01 | Rigerna Therapeutics Beijing Co Ltd | Compound, conjugate, composition and uses thereof |
| AU2024312039A1 (en) * | 2023-06-21 | 2026-01-22 | Changzhou Hansoh Pharmaceutical Co., Ltd. | Sirna, conjugate which contain sirna, pharmaceutical composition and uses thereof |
| CN117050998B (zh) * | 2023-08-25 | 2024-02-09 | 青岛农业大学 | 一种miRNA在防治溴氰虫酰胺抗性烟粉虱中的应用 |
| WO2025143000A1 (ja) * | 2023-12-27 | 2025-07-03 | 東亞合成株式会社 | Ｃ３ ｒｎａ配列に基づく新規二本鎖ｒｎａ及びその利用 |
| WO2025168134A1 (zh) * | 2024-02-08 | 2025-08-14 | 北京安龙生物医药有限公司 | 靶向补体成分c3基因的寡核苷酸及其用途 |
| CN121592644A (zh) * | 2024-08-16 | 2026-03-03 | 施能康生物医药（苏州）有限公司 | 靶向C3补体的RNAi试剂及其用途 |
| WO2026082188A1 (zh) * | 2024-10-17 | 2026-04-23 | 浙江扬厉医药技术有限公司 | 抑制C3表达的双链siRNA以及其缀合物 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3526328A4 (en) * | 2016-10-17 | 2020-05-27 | Apellis Pharmaceuticals, Inc. | COMBINATION THERAPY FOR C3 INHIBITION |
| CA3078971A1 (en) * | 2017-11-01 | 2019-05-09 | Alnylam Pharmaceuticals, Inc. | Complement component c3 irna compositions and methods of use thereof |
-
2022
- 2022-05-26 EP EP22812151.3A patent/EP4346844A4/en active Pending
- 2022-05-26 US US18/563,184 patent/US20250002910A1/en active Pending
- 2022-05-26 JP JP2023572828A patent/JP2024521792A/ja active Pending
- 2022-05-26 WO PCT/US2022/031115 patent/WO2022251484A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023103244A5 (cg-RX-API-DMAC7.html) | ||
| CA2458806C (en) | Antisense oligonucleotide against human ache and uses thereof | |
| JP2021006029A5 (cg-RX-API-DMAC7.html) | ||
| US7737265B2 (en) | RNAi modulation of HIF-1 and therapeutic uses thereof | |
| JP2025165939A5 (cg-RX-API-DMAC7.html) | ||
| JP2023052363A5 (cg-RX-API-DMAC7.html) | ||
| EP2029746B1 (en) | Compositions and methods for sirna inhibition of angiogenesis | |
| JP2023518409A5 (cg-RX-API-DMAC7.html) | ||
| KR102339886B1 (ko) | 연결 조직 성장 인자를 표적화하는 rna 복합체를 사용한 특발성 폐 섬유증의 치료 방법 | |
| JP2016506240A5 (cg-RX-API-DMAC7.html) | ||
| HRP20180093T1 (hr) | Pripravci i postupci za inhibiciju ekspresije transtiretina | |
| RS67250B1 (sr) | Metode i kompozicije za lečenje poremećaja povezanog sa serpinc1 | |
| KR20080041145A (ko) | 암 및 다른 신생혈관증식 질환을 치료하기 위한 ＲＮＡｉ치료제의 조성물 및 방법 | |
| KR20120038546A (ko) | ＨＩＦ-1 알파의 ｓｉＲＮＡ 억제를 위한 조성물 및 방법 | |
| RU2013148024A (ru) | Композиции и способы ингибирования экспрессии гена tmprss6 | |
| AU2004233043A1 (en) | Compositions and methods for siRNA inhibition of angiopoietin 1 and 2 and their receptor Tie2 | |
| JP2024508896A5 (cg-RX-API-DMAC7.html) | ||
| AU2007292229A1 (en) | SiRNA and methods of manufacture | |
| JP2024516356A5 (cg-RX-API-DMAC7.html) | ||
| JP2009535039A5 (cg-RX-API-DMAC7.html) | ||
| JP2024529437A5 (cg-RX-API-DMAC7.html) | ||
| US7964575B2 (en) | Use of a galectin-1-targeted RNAi-based approach for the treatment of cancer | |
| JP2024002985A5 (cg-RX-API-DMAC7.html) | ||
| US20040220131A1 (en) | Method for treatment of cancerous angiogenic disorders | |
| WO2004092379A9 (en) | Method for treatment of angiogenic disorders |